Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,445,500 | 2,938,000 | 2,685,600 | 3,272,800 | 3,140,600 |
| Marketable Securities | 1,226,000 | 1,288,300 | 1,156,400 | 789,400 | 757,900 |
| Receivables | 973,000 | 912,100 | 892,800 | 902,600 | 751,900 |
| Inventories | 1,119,000 | 1,126,200 | 1,140,900 | 1,141,700 | 1,113,900 |
| Other current assets | 329,500 | 339,300 | 358,000 | 360,700 | 337,100 |
| TOTAL | $6,228,700 | $6,738,900 | $6,358,900 | $6,577,200 | $6,212,700 |
| Non-Current Assets | |||||
| PPE Net | 1,823,100 | 1,811,900 | 1,743,300 | 1,726,600 | 1,698,300 |
| Investments And Advances | 285,600 | 278,600 | 274,700 | 0 | 277,900 |
| Intangibles | 3,047,500 | 2,896,800 | 2,899,300 | 2,949,500 | 2,953,600 |
| Other Non-Current Assets | 1,936,300 | 1,971,000 | 1,995,999 | 2,235,400 | 1,879,801 |
| TOTAL | $7,092,500 | $6,958,300 | $6,913,299 | $6,911,500 | $6,809,601 |
| Total Assets | $13,321,200 | $13,697,200 | $13,272,200 | $13,488,700 | $13,022,300 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 181,100 | 227,500 | 165,000 | 162,100 | 172,400 |
| Accrued Expenses | 1,203,600 | 1,561,700 | 1,393,900 | 1,214,400 | 1,196,400 |
| TOTAL | $1,409,000 | $1,813,700 | $1,588,000 | $1,404,700 | $1,394,800 |
| Non-Current Liabilities | |||||
| Long Term Debt | 598,500 | 598,300 | 598,200 | 598,000 | 597,800 |
| Other Non-Current Liabilities | 986,200 | 947,600 | 881,800 | 881,200 | 839,700 |
| TOTAL | $1,584,700 | $1,545,900 | $1,479,200 | $1,477,500 | $1,435,900 |
| Total Liabilities | $2,993,700 | $3,359,600 | $3,067,200 | $2,882,200 | $2,830,700 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 575,800 | 580,800 | 580,300 | 587,100 | 586,600 |
| Common Shares | 660,000 | 658,700 | 658,200 | 657,600 | 655,900 |
| Retained earnings | 14,621,200 | 14,240,500 | 14,149,300 | 13,858,200 | 13,525,000 |
| Other shareholders' equity | -221,200 | -238,000 | -249,900 | -203,300 | -191,500 |
| TOTAL | $10,327,500 | $10,337,600 | $10,205,000 | $10,606,500 | $10,191,600 |
| Total Liabilities And Equity | $13,321,200 | $13,697,200 | $13,272,200 | $13,488,700 | $13,022,300 |